Cibus (CBUS) Stock Price, News & Analysis

Company Overview

Cibus is a plant biotechnology company that specializes in developing novel crop traits through precision gene editing. Using its proprietary Rapid Trait Development System (RTDS), the company targets improvements in yield, stress tolerance and quality without introducing foreign DNA, enabling what it terms “non-transgenic” enhancements. Cibus’s platform supports accelerated discovery and development of traits that address key challenges in modern agriculture, including climate resilience, herbicide tolerance and nutritional performance.

Founded in 1999 and headquartered in San Diego, California, Cibus has built a track record of innovation in the agricultural biotechnology sector. The company pursued its initial public listing in 2017, providing capital to expand its R&D operations and forge collaborations with leading seed and crop protection firms. Over more than two decades, Cibus has scaled its research capabilities, adding laboratory, greenhouse and field-testing facilities to advance a growing pipeline of gene-edited trait candidates.

Cibus focuses on major row and specialty crops such as canola, potato, tomato and rice, working closely with seed companies and farmers to integrate its traits into commercial varieties. The company offers trait development services, licensing arrangements and co-development partnerships, leveraging its RTDS expertise to tailor solutions for diverse agronomic needs. Cibus has also engaged in strategic collaborations to explore applications of its technology in new crop genomes and trait classes.

Serving markets in North America, Europe and select emerging regions, Cibus collaborates with regional breeding programs and distribution partners to accelerate market adoption. The company is led by President and Chief Executive Officer Rob Rasmus, whose management team brings deep experience in plant biotechnology, seed industry operations and agricultural innovation. Under this leadership, Cibus continues to advance its mission of delivering sustainable, science-driven crop improvements for global agriculture.

Key Stats

• Today's Range: $1.55 to $1.64
• 50-Day Range: $1.38 to $3.36
• 52-Week Range: $1.38 to $10.77
• Volume: 268,693 shs
• Average Volume: 235,371 shs
• Market Capitalization: $50.95 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.00
• Consensus Rating: Buy

Cibus Stock Analysis - MarketRank™

Cibus scored higher than 69% of companies evaluated by MarketBeat, and ranked 79th out of 154 stocks in the consumer staples sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Cibus has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Cibus has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Cibus are expected to decrease in the coming year, from ($2.96) to ($3.02) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cibus is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cibus is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cibus has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.58% of the float of Cibus has been sold short.

Short Interest Ratio / Days to Cover

Cibus has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cibus has recently decreased by 27.03%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cibus does not currently pay a dividend.

Dividend Growth

Cibus does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.58% of the float of Cibus has been sold short.

Short Interest Ratio / Days to Cover

Cibus has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cibus has recently decreased by 27.03%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Cibus has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Consumer Staples companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Cibus this week, compared to 3 articles on an average week.

Search Interest

4 people have searched for CBUS on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Cibus to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cibus insiders have not sold or bought any company stock.

Percentage Held by Insiders

49.40% of the stock of Cibus is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 33.81% of the stock of Cibus is held by institutions.

CBUS Stock Analysis - Frequently Asked Questions

How have CBUS shares performed this year?

Cibus' stock was trading at $2.78 on January 1st, 2025. Since then, CBUS shares have decreased by 43.9% and is now trading at $1.56.

How were Cibus' earnings last quarter?

Cibus, Inc. (NASDAQ:CBUS) issued its quarterly earnings data on Thursday, May, 8th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.70) by $0.04. The firm earned $1.03 million during the quarter, compared to the consensus estimate of $1.15 million. Cibus had a negative net margin of 5,784.87% and a negative trailing twelve-month return on equity of 53.20%.

When did Cibus IPO?

Cibus (CBUS) raised $100 million in an initial public offering on Thursday, February 14th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Piper Jaffray acted as the underwriters for the IPO.

How do I buy shares of Cibus?

Shares of CBUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cibus own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cibus investors own include NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD), Visa (V), Netflix (nflx) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Consumer Staples
• Industry: AGRI OPERATIONS
• Sub-Industry: Chemicals
• Current Symbol: NASDAQ:CBUS
• Previous Symbol: NASDAQ:CBUS
• CIK: 1705843
• Web: www.cibus.com
• Phone: (858) 450-0008
• Fax: N/A
• Employees: 48
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Cibus: $22.00
• High Price Target: $25.00
• Low Price Target: $17.50
• Potential Upside/Downside: +1,310.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($10.98)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$251.39 million
• Net Margins: -5,784.87%
• Pretax Margin: -6,422.14%
• Return on Equity: -53.20%
• Return on Assets: -18.04%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.23
• Quick Ratio: 1.23

Sales & Book Value

• Annual Sales: $4.75 million
• Price / Sales: 10.72
• Cash Flow: $3.90 per share
• Price / Cash Flow: 0.40
• Book Value: $3.11 per share
• Price / Book: 0.50

Miscellaneous

• Outstanding Shares: 32,658,000
• Free Float: 22,482,000
• Market Cap: $50.95 million
• Optionable: Optionable
• Beta: 1.69